Mesenchymal stem cells (MSCs) are being clinically explored as a new therapeutic for treating a variety of immune-mediated diseases, and the biologic behavior of endogenous MSCs in inflamed tissues was found to be defective, which may contribute to diseases.^[@bib1],\ [@bib2],\ [@bib3]^ Periodontal ligament stem cells (PDLSCs), a group of periodontal ligament tissue-derived MSCs, had been isolated from periodontal tissues.^[@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ Our previous research suggested that osteogenic differentiation of PDLSCs from periodontitis was inhibited by inflammation, and could be regulated by *β*-catenin signaling.^[@bib8],\ [@bib9]^ However, the underlying molecular mechanism governed directly by inflammation is still poorly understood.

Nuclear factor-*κ*B (NF-*κ*B) is a transcription factor thought to have an important role in the onset of inflammation. Activation of NF-*κ*B signaling induces transcription of proinflammatory genes by nuclear translocation of a transcription factor complex.^[@bib10],\ [@bib11]^ The connection between NF-*κ*B and osteoblasts stems from initial observations that inflammation, and in particular TNF-*α*, inhibits bone formation.^[@bib12],\ [@bib13],\ [@bib14]^ However, it remains to be understood whether inflammatory cytokines in periodontitis could activate NF-*κ*B signaling leading to impaired differentiation of PDLSCs.

Glycogen synthase kinase 3*β* (GSK-3*β*) is known to modulate cell apoptosis and differentiation through multiple intracellular signaling pathways. GSK-3 is now known to target multiple cell regulatory proteins and to be controlled by both WNT signaling and the PI3K/Akt pathway. In addition to *β*-catenin, the targets of GSK-3 that have been implicated in the regulation of cell proliferation and differentiation include several transcription factors of NF-*κ*B signaling.^[@bib15],\ [@bib16],\ [@bib17],\ [@bib18],\ [@bib19]^ Recently, some studies have found that GSK 3*β* could modulate both NF-*κ*B and *β*-catenin activity through phosphorylation or transcriptional regulation.^[@bib13],\ [@bib20],\ [@bib21]^ However, it is not clear whether GSK 3*β* regulates NF-*κ*B and *β*-catenin activity in inflammation.

Previously, it was reported that nuclear translocation of p65 in response to inflammation was mediated through NF-*κ*B signaling.^[@bib12],\ [@bib22],\ [@bib23]^ We found an unexpected result showing that p65 nuclear translocation was inhibited after LiCl stimulation only in periodontitis PDLSCs but not in healthy PDLSCs, as well as higher activation of *β*-catenin activity in periodontitis as expected. Then we rescued the osteogenic potency of PDLSCs from periodontitis using BAY 11-7082 (inhibitor of NF-*κ*B), which could also upregulate *β*-catenin expression only in PDLSCs from periodontitis patients (P-PDLSCs).

Results
=======

Inhibition of GSK-3*β* could restore osteogenic differentiation of P-PDLSCs
---------------------------------------------------------------------------

In our earlier study, WNT signaling is implicated in regulating osteogenic differentiation of P-PDLSCs. Next, considering that GSK-3*β* is a key modulator in the WNT pathway, we want to assess the role of GSK-3*β* after using a specific inhibitor LiCl. LiCl could functionally affect the activity of GSK-3*β* of PDLSCs. When the PDLSCs were cultured in osteogenic differentiation medium with LiCl (10 mM), the phosphorylation level of GSK-3*β* was significantly increased in both PDLSCs. The results were consistent with previous research ([Figure 1a](#fig1){ref-type="fig"}).

We observed that LiCl promoted the ALP activity of P-PDLSCs, as well as staining. However, ALP activity and staining were inhibited, obviously, in H-PDLSCs ([Figure 1b](#fig1){ref-type="fig"}). The mRNA and protein levels of osterix were also consistent with these results ([Figures 1c and d](#fig1){ref-type="fig"}). These data suggested that GSK-3*β* showed the opposite effect on osteogenic differentiation of PDLSCs from different microenvironments.

GSK-3*β* modulated WNT and NF-*κ*B signaling in PDLSCs
------------------------------------------------------

GSK-3*β*, a component of the canonical WNT signaling pathway, is implicated in the regulation of bone mass.^[@bib24]^ To gain further insight into the different GSK-3*β*-mediated effects on PDLSCs, we tested two key signaling pathways WNT and NF-*κ*B, which might be regulated by GSK-3*β*. The addition of LiCl in our assay system significantly blocked the activity of NF-*κ*B in P-PDLSCs, whereas it did not affect the NF-*κ*B activation of H-PDLSCs. We then directly tested the WNT signaling using the active-*β*-catenin antibody and found that WNT signaling was activated after LiCl treatment in H-PDLSCs, but was slightly decreased in P-PDLSCs ([Figure 2b](#fig2){ref-type="fig"}). Moreover, we did not observe any transcription change of p65 and *β*-catenin in both PDLSCs after LiCl stimulation ([Figure 2a](#fig2){ref-type="fig"}). These results suggested that WNT signaling might be mediated by osteogenesis in H-PDLSCs, and NF-*κ*B signaling was competent with WNT-regulating osteogenic differentiation of P-PDLSCs.

Activation of GSK-3*β* could decrease the osteogenic differentiation of PDLSCs
------------------------------------------------------------------------------

The results of our experiments suggest that GSK-3*β* inhibition only increases the osteogenesis of P-PDLSCs. Therefore, we examined the possibility that the status of GSK-3*β* kinase activity is a determining factor in osteogenic differentiation of P-PDLSCs. To test this hypothesis, we further analyzed the osteogenic expression profile of PDLSCs by promoting GSK-3*β* kinase activity. LY 294002, a small-molecule inhibitor of the PI3K signal pathway, could inhibit GSK-3*β* phosphorylation as shown in a previous study ([Figure 3c](#fig3){ref-type="fig"}). It is noteworthy that LY 294002 exposure significantly decreased the osteogenesis of P-PDLSCs, as well as of H-PDLSCs, which was indicated by a 1.5-fold reduction of ALP activity ([Figure 3a](#fig3){ref-type="fig"}). Real-time PCR and western blot analysis revealed that the levels of the osteoblast-specific gene Osterix was higher in PDLSCs compared with the cells treated with LY 294002 ([Figure 3b](#fig3){ref-type="fig"}).

We next investigated the impact of p65 and *β*-catenin nuclear translocation after LY 294002 addition. In accordance with phosphorylation of GSK-3*β*, LY 294002 treatment significantly upregulated p65 and downregulated *β*-catenin translocation in the nucleus, but had no effect on p65 and *β*-catenin in the cytoplasm ([Figure 3c](#fig3){ref-type="fig"}). Recent studies implied a functional role for GSK-3*β* in regulating phosphorylation of I*κ*B*α*. I*κ*B*α* predominantly regulates the function of p65 nuclear localization in the classical pathway.^[@bib22]^ However, we found that the pattern of p-I*κ*B*α* has no effect on PDLSCs under LY 294002 treatment ([Figure 3c](#fig3){ref-type="fig"}). In addition, on adding LY 294002 to H-PDLSCs, it was found that P-PDLSCs and H-PDLSCs with TNF-*α* had a similar effect on the activity of WNT and NF-*κ*B signaling. These findings suggest that GSK-3*β* is involved in osteogenic differentiation of PDLSCs. However, the effect of LY 294002 treatment is not dependent only on GSK-3*β* activity.

Higher activation of NF-*κ*B in P-PDLSCs and decreased osteogenesis was rescued by inhibition of NF-*κ*B
--------------------------------------------------------------------------------------------------------

Our results support a notion that GSK-3*β* mediated osteogenic differentiation by activating NF-*κ*B signaling in P-PDLSCs. To determine whether NF-*κ*B signaling is indeed implicated in defective osteogenesis, we next compared the status of NF-*κ*B signaling between H-PDLSCs and P-PDLSCs. ALP staining showed that osteogenic differentiation was defective in P-PDLSCs ([Figure 4a](#fig4){ref-type="fig"}). Real-time PCR and western blot analysis were performed to determine the osteogenic marker genes and the protein levels. Osterix gene expression in P-PDLSCs was lower than that in H-PDLSCs ([Figure 4b](#fig4){ref-type="fig"}). BAY 11-7082, an irreversible inhibitor of I*κ*B*α* phosphorylation, could block NF-*κ*B signaling. BAY 11-7082 treatment significantly increased the osteogenic differentiation potential of P-PDLSCs. However, BAY 11-7082 did not affect the differentiation of H-PDLSCs ([Figure 4](#fig4){ref-type="fig"}). To further confirm these findings, another inhibitor PDTC, which selectively inhibits NF-*κ*B activation, was also used in our work. Similarly, PDTC rescued the defective osteogenesis of P-PDLSCs, but had no effect on H-PDLSCs ([Figure 4](#fig4){ref-type="fig"}).

These data indicated that inhibition of NF-*κ*B could recover the osteogenic differentiation potential of P-PDLSCs. Now that our results showed that WNT and NF-*κ*B signaling modulated osteogenic differentiation of PDLSCs together, we also assessed the effect of NF-*κ*B on the regulation of WNT signaling. Interestingly, BAY 11-7082 did not affect the activity of *β*-catenin, but upregulated the expression of *β*-catenin through an unknown mechanism only in P-PDLSCs; real-time PCR and western blot analysis showed a similar pattern ([Figure 5](#fig5){ref-type="fig"}). The results again suggest that NF-*κ*B has a critical role in regulating osteogenesis of P-PDLSCs.

Discussion
==========

MSCs that could differentiate into osteoblasts under appropriate conditions have a great application prospect in treating bone diseases. PDLSCs are a population of tissue-specific MSCs that could be obtained very easily especially in periodontitis. However, P-PDLSCs exhibit a lower multidifferentiation potential than H-PDLSCs. Therefore, we focus our investigation on how to improve the differentiation potential of P-PDLSCs in order to make better use of the stem cells.

The present study establishes the important role of NF-*κ*B signaling in osteoblastic differentiation and inflammation. We have uncovered a signal circuit regulating osteogenesis interfered by inflammation between NF-*κ*B and *β*-catenin signaling ([Figure 6](#fig6){ref-type="fig"}). Our studies demonstrate that (i) GSK-3*β* acts as a mediator of NF-*κ*B and *β*-catenin signaling and regulates osteogenesis of PDLSCs; (ii) the inhibitor of PI3K LY 294002 modulates both NF-*κ*B and *β*-catenin signaling in PDLSCs with and without inflammation; (iii) BAY 11-7082 blocks p65 nuclear translocation in P-PDLSCs, and rescues the differentiation potential of PDLSCs in inflammation; and that (iv) BAY 11-7082 also influences *β*-catenin expression in P-PDLSCs through unknown mechanisms. We propose that NF-*κ*B signaling may be more important than *β*-catenin signaling in the regulatory network response to inflammation, leading to defective osteogenic differentiation in PDLSCs.

TNF-*α* was a main inflammatory cytokine of periodontitis. In our previous studies, we found that H-PDLSCs impaired by TNF-*α* and P-PDLSCs exhibit a lower differentiation potential than H-PDLSCs, and *β*-catenin signaling negatively regulates the osteogenic differentiation of PDLSCs in inflammatory microenvironments or when treated with inflammatory cytokines.^[@bib8],\ [@bib9]^ However, the mechanism as to how inflammation leads to modulation of *β*-catenin signaling and decreased differentiation potential remains unclear. As TNF-*α* can directly activate NF-*κ*B signaling in many different cells through the receptor, it may have an intrinsic effect on the function of PDLSCs through the NF-*κ*B pathway.^[@bib14],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ However, there was no research carried out on this pathway in PDLSCs from periodontitis.

To further confirm the role of NF-*κ*B in PDLSCs, we compared NF-*κ*B signaling in P-PDLSCs and H-PDLSCs after osteogenic induction. Then we identified a model between H-PDLSCs and P-PDLSCs by modulating GSK-3*β* activity, because both NF-*κ*B and *β*-catenin activity could be influenced by GSK-3*β*. The proteasomal degradation of *β*-catenin mediated by GSK-3*β* and the destruction complex is the central step in the canonical WNT signaling pathway.^[@bib30],\ [@bib31]^ However, it was reported that GSK-3*β* affects the nuclear accumulation of NF-*κ*B and the binding to its target gene promoters.^[@bib32],\ [@bib33],\ [@bib34]^ In this study, it was found that GSK-3*β* could mediate *β*-catenin and NF-*κ*B signaling through the regulation of translocation of *β*-catenin and p65 to the nucleus. Interestingly, I*κ*B*α* and its phosphorylation were unaffected by the activation change of GSK-3*β*, although a recent study indicated that the high levels of GSK-3*β* activity in quiescent cells repress gene expression by negatively regulating NF-*κ*B through the inhibition of I*κ*B kinase.^[@bib35]^ LY 294002 enhances the phosphorylation of NF-*κ*B p65 on Ser529 and Ser536 residues, which results in enhanced p65 transactivation activity.^[@bib36]^ On the other hand, GSK-3*β* could directly regulate phosphorylation of p65 at Ser(468) in unstimulated cells, thereby controlling the activity of NF-*κ*B.^[@bib33]^ The activity of p65, which is targeted by various signaling pathways and protein kinases, may be enhanced by PI3K or GSK-3β not through the upstream gene IκB. It is possible that the trend of p65 may be not only be essential for osteogenesis but also for protection of PDLSCs from TNF-*α*-induced apoptosis or other feedback regulation *β*-catenin signaling.^[@bib37],\ [@bib38]^ However, the mechanism by which GSK-3*β* regulates the balance of *β*-catenin and NF-*κ*B signaling in PDLSCs is still unknown and needs further study.

BAY 11-7082, an inhibitor of I*κ*B kinase activity, has been studied in anti-inflammatory and apoptosis researches.^[@bib39],\ [@bib40],\ [@bib41]^ However, its function in osteogenesis is still unclear. In the study of NF-*κ*B signaling, we have discovered that BAY 11-7082 could inhibit NF-*κ*B signaling and that it improved the osteogenic potential of H-PDSLCs treated with TNF-*α* or P-PDLSCs. These data suggest that canonical NF-*κ*B signaling indeed mediated the osteogenesis progress influenced by inflammation. To our knowledge, this is the first study to show the increased osteogenesis by NF-*κ*B inhibitors in PDLSCs using a clinical patient model. Against all expectations, BAY 11-7082 could also affect *β*-catenin signaling. Although some reports have elucidated a cross talk between NF-*κ*B and *β*-catenin signaling through alterations in GSK-3*β*,^[@bib34],\ [@bib42],\ [@bib43],\ [@bib44]^ NF-*κ*B might influence the location of *β*-catenin through an unknown mechanism, and the hypothesis needs verification in future work.

In summary, our study has provided new insight into molecular mechanisms of NF-*κ*B, showing that it acts as a regulator controlling multiple facets that are critical for the osteogenic differentiation of PDLSCs obtained from inflammatory microenvironments. The I*κ*Bα phosphorylation inhibitor can partially restore P-PDLSCs\' osteogenic capacity, suggesting that NF-κB could mediate the osteogenic differentiation of P-PDLSCs. Our future efforts will be focused on developing an in-depth understanding of the cross talk between NF-*κ*B and *β*-catenin signaling, which could have a profound impact on improving bone regeneration and repair in inflammatory microenvironments.

Materials and Methods
=====================

Study samples and cell culture
------------------------------

Healthy periodontal tissues were obtained from healthy human premolars or the third molars extracted from 10 systemically healthy adults (27--32 years of age) for orthodontic purposes. The inflammatory tissues were isolated from eight patients with moderate or severe chronic periodontitis (30--41 years of age) for orthodontic or periodontal flap surgery reasons. The clinical diagnosis of chronic periodontal disease was based on clinical examination and radiography assessment. Patients with periodontitis are defined as those having at least one periodontal probing pocket depth of ⩾5 mm, with bleeding on probing and radioraphic evidence of alveolar bone loss(2/3). All of the surgical procedures were performed for the purpose of treatment, and all samples were collected at the Dental Clinic of the Fourth Military Medical University. The study was approved by the hospital ethics committee, and informed consent was provided by all patients.

PDLSCs were isolated and cultured according to previously reported protocols, as follows.^[@bib8],\ [@bib9]^ We gently washed the teeth with sterile phosphate-buffered solution (PBS) (Boster, Wuhan, China) and separated PDL tissues from the middle part of the root surface using a scalpel from healthy (H-PDLSCs) orP-PDLSCs patients. H-PDLSCs and P-PDLSCs were obtained using the limiting dilution technique. After 2--4 weeks, the single-cell-derived clones were harvested and mixed together. ---Two to four passages of multiple colony-derived H-PDLSCs and P-PDLSCs were used in our experiments.

Induction of osteogenic differentiation
---------------------------------------

H-PDLSCs and P-PDLSCs (P4) were seeded into six-well culture dishes (Costar, Cambridge, MA, USA) at 1 × 10^5^ cells/well and cultured until they reached 80% confluence. The culture medium for osteogenic differentiation comprised a-MEM (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS) (Gibco), 100 nM dexamethasone (Sigma, St Louis, MO, USA), 50 *μ*g/ml of ascorbic acid, and 10 mM *β*-glycerophosphate(Sigma). The medium was changed every 2 days. After 2--4 weeks of the induction of osteogenic differentiation, the cells were stained with alkaline phosphatase (ALP )stain or alizarin red stain at specific time points according to the manufacturer\'s protocol. ALP staining and ALP activity were determined using the BCIP/NBT ALP color development kit (Beyotime, Haimen, China) and the ALP (AKP/ALP) detection kit (BioVision, Milpitas, CA, USA).

Total RNA extraction and RT- PCR
--------------------------------

Total RNA was extracted from *in vitro* culture samples using TRIzol reagent (Invitrogen, Grand Island, NY, USA). Reverse transcriptase-polymerase chain reaction was performed with 1 *μ*g of RNA using a PrimeScript RT reagent kit (TaKaRa, Dalian, China). The primer sequences used in the experiment were listed in [Table 1](#tbl1){ref-type="table"}, and related genes were quantified by real-time RT-PCR using the SYBR Premix Ex Taq II kit (TaKaRa) and the CFX96 Touch Real-Time PCR Detection System (Bio-rad, Hercules, CA, USA).

LiCl/ LY 294002/ BAY 11-7082/ PDTC treatment
--------------------------------------------

The subset of these cultures were separated and treated with the GSK-3*β* inhibitor (LiCl) at a concentration of 10 mM, phosphatidylinositol 3-kinase (PI3K inhibitor; LY 294002) at a concentration of 20 *μ*M, NF-*κ*B inhibitor BAY 11-7082 at a concentration of 100 ng/ml and pyrrolidine dithiocarbamate (PDTC) at a concentration of 50 ng/ml. Cells were seeded at a density of 5000 cells/cm^2^ in T25 culture flasks and expanded in *α*-MEM (10% FBS) until they reached 80% confluence. The culture medium was then changed to the basal or osteogenic medium, which contained LiCl or LY 294002 or BAY 11-7082 or PDTC used for the PDLSC cultures as described above and changed every 2 days. On day 7, after the medium was replaced with fresh medium 1 h later, we harvested the cells and subjected them to assays for *in vitro* osteogenic differentiation.

Protein isolation and western blot analysis
-------------------------------------------

Total proteins were extracted with lysis buffer (10 mM Tris-HCL, 1 mM EDTA, 1% sodium dodecyl sulfate, 1% Nonidet P-40, 1 : 100 proteinase inhibitor cocktail, 50 mM *β*-glycerophosphate, 50 mM sodium fluoride). Cytoplasmic and nuclear proteins were extracted using the Nuclear Extraction Kit according to the manufacturer\'s protocols (Millipore, Billerica, MA, USA). The protein concentration in the extracted lysates was determined with a protein assay kit (Beyotime) according to the manufacturer\'s recommended protocol. Aliquots of 20--60 *μ*g per sample were separated by 10% SDS-polyacrylamide gel electrophoresis, transferred to the polyvinylidene fluoride membranes (Millipore) and blocked with 5% nonfat milk powder in PBST (PBS with 0.1% Tween); next, they were incubated with the following primary antibodies overnight: anti-Osterix, anti-GSK-3*β*, anti-*β*-catenin, anti-*β*-actin (Abcam, Cambridge, UK), anti-p-GSK-3*β*, anti-p65, anti-p-p65, anti-I*κ*B*α*, anti-p- I*κ*B*α*, anti-HDAC1 (Cell Signaling Technology, Beverly, MA, USA) and anti-active-*β*-catenin (Millipore). The membranes were then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibody (Boster, Wuhan, China). The blots were visualized using an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer\'s recommended instructions.

Statistical analysis
--------------------

All results are presented as mean (±S.D.) from at least three independent experiments and analyzed by a two-tailed unpaired Student\'s *t-*test using the SPSS software (IBM, Armonk, NY, USA). *P-*values \<0.05 were considered to be statistically significant.
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![Inhibition of GSK-3*β* rescues the osteogenic differentiation of P-PDLSCs but decreases osteogenic differentiation of H-PDLSCs. H-PDLSCs and P-PDLSCs were treated with or without LiCl along with osteogenic differentiation medium for 7 days. (**a**) The expression of p-GSK-3*β* and GSK-3*β* was examined by western blot analysis. (**b**) Quantification of ALP activity staining. (**c**,**d**) Real-time RT-PCR and western blot analysis of the osteoblast marker gene (Osterix, normalized to *β*-actin) on day 7. Data represent the means±S.D. \**P*\<0.05 (*n*=3)](cddis201314f1){#fig1}

![Effects of GSK-3*β* activity on NF-*κ*B and WNT signaling in PDLSCs. (**a**) The expression of NF-*κ*B (p65) and *β*-catenin was examined by Real-time RT-PCR (*n*=3). (**b**) The activation of NF-*κ*B (phosphorylated p65, pNF-*κ*B) and *β*-catenin (specific for the active form of *β*-catenin, dephosphorylated on Ser37 or Thr41) and actin was examined by western blot analysis](cddis201314f2){#fig2}

![Increased GSK-3*β* activity blocked osteogenic differentiation of PDLSCs. H-PDLSCs, P-PDLSCs and H-PDLSCs treated with TNF-*α* were grown in the presence of osteogenic medium with or without LY 294002. (**a**) Osteoblastic differentiation was determined by ALP staining and activity at day 7. (**b**) Real-time RT-PCR and western blot analysis of the osteoblast marker gene (Osterix, normalized to *β*-actin) on day 7. Data represent the means±S.D. \**P*\<0.05 (*n*=3). (**c**) Cytoplasmic p-GSK-3*β*, *β*-catenin, p-IκBα and p65 levels and nuclear *β*-catenin and p65 levels were tested after 7 days of culture in osteogenic medium by western blot analysis. *β*-Actin and HDAC1were used as the internal control](cddis201314f3){#fig3}

![Inhibition of NF-*κ*B restored osteogenesis of P-PDLSCs. H-PDLSCs and P-PDLSCs were treated with BAY 11-7082 (H-PDLSCs as a control), and then were cultured with osteoblastic differentiation medium for additional 7 days. (**a**) Osteoblastic differentiation was determined by ALP staining and activity at day 7. (**b**,**c**) The PDLSCs were treated with another inhibitor PDTC, and the expression of the osteoblast-related gene Osterix was measured by Real-time RT-PCR and western blot analysis at day 3. The expression levels were normalized to *β*-actin. Data were shown as means±S.D. \**P*\<0.05, *n*=3](cddis201314f4){#fig4}

![Inhibition of NF-*κ*B did not affect the activity of *β*-catenin but increased the *β*-catenin expression in P-PDLSCs. To further confirm the relationship between NF-*κ*B and *β*-catenin signaling in osteogenic differentiation, H-PDLSCs and P-PDLSCs had been treated with BAY 11-7082 or with DMSO (as control). (**a**) The expression of NF-*κ*B (p65) and *β*-catenin was examined by real-time RT-PCR (*n*=3). \**P*\<0.05. (**b**) The expression of pNF-*κ*B p-p65, NF-*κ*B (p65), active-*β*-catenin, *β*-catenin and actin was examined by western blot analysis](cddis201314f5){#fig5}

![Schematic of GSK-3*β*-mediated NF-*κ*B signaling suppression of osteoblastic differentiation governed by inflammation. In P-PDLSCs, NF-*κ*B can be activated directly, but it can also be activated through inhibition of PI3K, which blocks the phosphorylation of GSK-3*β*, thereby leading to an increase of p65 and decrease of *β*-catenin in the nucleus. BAY 11-7082, an inhibitor of NF-*κ*B, can promote osteogenesis of PDLSCs by interfering with p65 nuclear translocation](cddis201314f6){#fig6}

###### Primer sequences and condition for reverse transcription-polymerase chain reaction

  **Gene**      **Primer sequence**
  ------------- -----------------------------------------
  *β-Actin*     
   Forward      5′-TGG CAC CCA GCA CAA TGA A-3′
   Reverse      5′-CTA AGT CAT AGT CCG CCT AGA AGC A-3′
                 
  *Osterix*     
   Forward      5′-GGA CCA TTC CCA CGT CTT CAC-3′
   Reverse      5′-CCT TGT AGC CAG GCC CAT TG-3′
                 
  *β-Catenin*   
   Forward      5′-AAT CTT GCC CTT TGT CCC G-3′
   Reverse      5′-GGT TGT GAA CAT CCC GAG C-3′
                 
  *P65*         
   Forward      5′-GGG CAC GAT TGT CAA AGA TGG-3′
   Reverse      5′-AAG AAG CGG GAC CTG GAG CA-3′
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